
    
      This is a Phase 1, open-label, parallel group, single dose study to investigate the effect of
      hepatic impairment on the PK of glasdegib after administration of a single oral 100 mg dose.
      Subjects with moderate or severe hepatic impairment will be enrolled, followed by healthy
      subjects with normal hepatic function who serve as matched controls.
    
  